Lowest Price Guaranteed From USD 5,899
Published
November 2021
Pages
402
View Count
23098
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Chronic diseases are considered to be the leading causes of deaths and disability. In fact, globally, such diseases are known to be responsible for two third of the overall deaths. Within the US, nearly 52% of the adult population is presently living with at least one chronic condition, while 27% of the US adults are suffering from multiple chronic conditions. Further, the financial burden associated with these diseases is currently estimated to be around USD 1 trillion in the US; this is anticipated to increase up to USD 6 trillion by 2050. In the past, the pharmaceutical industry has made significant efforts in integrating novel strategies and innovating patient-centric approaches to treat various chronic conditions. The current treatment options include oral and parenteral administration of the prescribed pharmacological interventions, physical therapies and use of digital therapeutic solutions. Among these, parenteral administration of drugs is the most common method, however, this approach lacks patient convenience because it involves frequent dosing and repeated hospital visits. In addition, it is associated with several other drawbacks and limitations, including dosing errors, risk of microbial contamination and needlestick injuries. These are known to be the primary factors affecting medication adherence and, thereby, have a significant impact on therapeutic outcomes. Over the last few years, the industry has seen the emergence of advanced drug delivery devices, such as wearable injectors, autoinjectors and pen injectors. These are the self-injection devices that have the capability of producing a sustained therapeutic effect, thereby improving patient adherence and efficacy of treatments. Such practices also allow reductions in costs and enable the optimal usage of healthcare resources.
The approval of novel drugs, specifically biologics that have high viscosity and cannot be administered in lower volume, has further led to an increased demand for advanced drug delivery devices. As a result, medical device industry has come up with several large volume wearable injectors suitable for the delivery of such molecules. These innovative injection systems offer numerous dosing options (basal, bolus or continuous), integrated safety mechanisms, along with minimal or no risk of needlestick injuries. In addition, these injectors can be used for the subcutaneous drug delivery and have become a preferred choice for administration of drugs in home-care setting. Moreover, the popularity of these devices have encouraged various pharmaceutical companies and medical device developers to further enhance the features of large volume injectors with artificial intelligence algorithms, integrated mobile applications with smart health monitoring, reminders, connectivity to web-based portals for sharing medical data, visual / audible drug delivery confirmation notifications, automatic drug reconstitution, and error alerts. Given the ongoing innovation in this field, we are led to believe that adoption of such devices is likely to increase at a significant pace, thereby driving the market growth over the coming years.
The “Large Volume Wearable Injectors Market by Type of Device (Infusion Pumps and Patch Pumps), Usability (Disposable and Reusable), Therapeutic Area (Cardiovascular Disorders, Infectious Diseases, Neurological Disorders Oncological Disorders and Others), Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa): Industry Trends and Global Forecasts (6th Edition), 2021-2035” report features an extensive study of the current market landscape and the likely future evolution of these self-injection devices, over the next fifteen years. It specifically lays emphasis on the emergence of patient-centric, convenient, cost-effective and user-friendly wearable drug delivery solutions that are capable of administering large volumes of a drug subcutaneously, in the home-care setting. In addition to other elements, the report includes:
One of the key objectives of the report was to estimate the existing market size and potential future growth opportunities for large volume wearable injectors. Based on parameters, such as the number of commercialized devices, number of devices under development, price of the device and the annual adoption rate, we have provided an informed estimate on the likely evolution of the market over the period 2021-2035. The report also features sales forecasts for the overall large volume wearable injectors market with a detailed market segmentation on the [A] type of device (patch pump, injector and infusion pump and injector), [B] usability (reusable and disposable), [C] therapeutic area (cardiovascular disorders, infectious diseases, neurological disorders, oncological disorders and others) and [D] key geographies (North America, Europe, Asia Pacific, Latin America, and Middle East and North Africa). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios namely the conservative, base and optimistic scenarios, which represent different tracks of the industry’s evolution.
The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. The opinions and insights presented in this study were influenced by discussions conducted with several stakeholders in this domain. The report features detailed transcripts of discussions held with the following individuals:
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Chapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on the current state of the large volume wearable injectors market in the short-mid term and long term.
Chapter 3 provides a general overview of large volume wearable injectors, highlighting the growing demand for medical devices that enable self-administration. The chapter lays emphasis on the need for such devices, in terms of the rising incidence and prevalence of chronic diseases. Additionally, it provides an overview of the different types of self-injection devices available in the market, listing their various advantages. It also features a brief discussion on the concerns related to the use of such devices.
Chapter 4 presents information on the large volume wearable injectors that can deliver non-insulin drugs. In addition, the chapter includes a detailed analysis of these injector devices based on various relevant parameters, such as the status of development, type of device (patch pump / injector and infusion pump / injector), route of administration (subcutaneous, intradermal, intramuscular and intravenous), therapeutic area, type of technology, type of dose (basal, bolus and both), mode of injection (needle, cannula and catheter), volume / storage capacity, actuation mechanism (electromechanical, rotary pump, cell / expanded battery, pressurized gas, osmotic pressure and others), usability (disposable and reusable), availability of prefilled drug reservoir, availability of connectivity, drug compatibility (biologics, small molecules, high volume and non-viscous) and type of drug container (cartridge, vial, syringe and minibag system). In addition, the chapter presents developer landscape, along with the information on year of establishment, company size, region of headquarters and location of headquarters and leading players for product manufacturing.
Chapter 5 presents information on the large volume drug device combination. In addition, the chapter includes a detailed analysis of these injector devices based on various relevant parameters, such as the status of development, type of device (patch pump / injector and infusion pump / injector), route of administration (subcutaneous, intradermal, intramuscular and intravenous), therapeutic areas, drug compatibility (biologics, small molecules, high volume and non-viscous), type of drug container (cartridge, drug reservoir and vial), type of dose administered (basal, bolus and both), mode of injection (needle, cannula and catheter), mechanism of action (electromechanical, rotary pump, cell / expanded battery, pressurized gas, osmotic pressure and others), type of technology, volume / storage capacity of the device and usability (disposable and reusable). In addition, the chapter presents developer landscape, along with the information on year of establishment, company size, location of headquarters and leading players for product manufacturing.
Chapter 6 presents information on the large volume wearable injectors designed for the delivery of insulin. In addition, the chapter includes a detailed analysis of these injector devices based on various relevant parameters, such as the status of development, type of device (patch pump / injector and infusion pump / injector), volume / storage capacity, usability (disposable and reusable), availability of prefilled drug reservoir, type of dose administered (basal, bolus and both), combination insulin, non-interoperable device, availability of continuous glucose monitoring (CGM) / blood glucose meter BGM systems, availability of automated insulin delivery (AID), automatic insulin delivery (AID) / artificial pancreas, connectivity and type of device control feature (remote control, smartphone control and control within device). In addition, the chapter presents developer landscape, along with the information on year of establishment, company size, location of headquarters and leading players for product manufacturing.
Chapter 7 presents an insightful competitiveness analysis of large volume wearable injectors based on the supplier power of the developers and key product specifications. The analysis was designed to enable various products to compare their existing capabilities with various devices developed by different developers to achieve a competitive edge in the industry.
Chapter 8 provides detailed profiles of the key players that develop large volume wearable injectors. Each profile presents a brief overview of the company, financial information (if available), product portfolio, recent developments and an informed future outlook.
Chapter 9 provides tabulated profiles of drug device combination products. Each profile includes drug specifications, mechanism of action, current status of development, dosage and sales information.
Chapter 10 features an in-depth analysis and discussion on the various partnerships inked between the players in this market, since 2015, covering merger and acquisitions, product development agreements, product development and commercialization agreement, product / technology integration agreements, product / technology agreements, distribution agreements, commercialization agreements, clinical trial agreements, licensing agreements, manufacturing agreements, service agreements, and other relevant deals.
Chapter 11 provides a detailed acquisition target analysis, taking into consideration the historical trend of the activity of the companies that have acquired other firms since 2001, offering a means for other industry stakeholders to identify potential acquisition targets.
Chapter 12 provides an in-depth patent analysis, presenting an overview of the filed / granted patents related to wearable injectors for the delivery of drugs in large volumes. For this analysis, we looked at the patents that have been filed by various players over the last two decades. The analysis highlights the key information and trends associated with these patents, including patent type (granted patents, patent applications and others), patent publication year, issuing authority / patent offices involved, patent age, CPC symbols, emerging focus areas, type of players (industry and non-industry players) and the leading industry players, non-industry players and individual patent assignees. The chapter also includes a patent benchmarking analysis, patent characteristics and patent valuation analysis.
Chapter 13 presents a list of marketed and pipeline molecules that are likely to be considered for delivery via large volume wearable injectors in the future, identified on the basis of an analysis of the potential candidates, taking into consideration the various parameters, such as status of development, dosage, dose concentration, route of administration, type of dose and drug sales (in case of marketed drugs). For the purpose of this analysis, we collated a list of over 100 top-selling marketed drugs, which were initially screened on the basis of route of administration (subcutaneous / intramuscular / intravenous). Additionally, we compiled a list of pipeline molecules that are being investigated for delivery via the aforementioned routes. The likelihood of delivery via a large volume wearable injector in the future was estimated using the weighted average method.
Chapter 14 presents a detailed clinical trial analysis of the complete and ongoing studies to evaluate the combinations of drugs and large volume wearable injectors based on various parameters, such as trial registration year, current trial phase, recruitment status, study design, type of sponsor / collaborator, most active players by number of registered trials, key focus area, therapeutic area, geographical distribution by number of clinical trial, geographical distribution by enrolled patient population and clinical endpoints.
Chapter 15 provides details on various investments that have been made into companies with proprietary large volume wearable injectors since 2014 to 2021 including seed financing, venture capital financing, capital raised from IPOs, equity and subsequent offerings, grants and debt financing. The investment instances have been analyzed based on various relevant parameters, such as year of investment, amount invested, type of funding, most active players (in terms of number of funding instances) and type of investor.
Chapter 16 includes a brief case study on the role of contract manufacturing organizations in the overall manufacturing process / supply chain of a wearable injector. It includes information on the services provided by such organizations for manufacturing of device components (primary containers), infusion sets, adhesives, closures and injection moldings. In addition, it includes a schematic world map representation highlighting the location of the CMOs and their device manufacturing service portfolio. Further, information on the design and development of medical devices is included.
Chapter 17 features a discussion on the various guidelines established by major regulatory bodies for medical device approvals across North America (the US, Canada and Mexico), Europe (the UK, France, Germany, Italy, Spain and rest of Europe), Asia-Pacific and rest of the world (Australia, Brazil, China, India, Israel, Japan, New Zealand, Singapore, South Africa, South Korea, Taiwan, and Thailand). The report also features an insightful multi-dimensional heat map analysis, featuring a comparison of the contemporary regulatory and reimbursement scenarios in key geographies across the globe.
Chapter 18 presents an insightful market forecast analysis, highlighting the future potential of large volume wearable injectors (for delivery of non-insulin drugs) till the year 2035. We have segregated the opportunity on the basis of the type of device (patch pump, injector and infusion pump and injector), usability (reusable and disposable), key therapeutic areas (cardiovascular disorders, infectious diseases, neurological disorders, oncological disorders and others) and key geographies (North America, Europe, Asia Pacific, Latin America and Middle East and North Africa). In addition, the chapter presents an opportunity analysis of the market for large volume wearable injectors for delivery of insulin, till the year 2035.
Chapter 19 presents a detailed discussion on the future opportunities of wearable injectors for large volume drug delivery. It also highlights the key parameters and trends that are likely to influence the future of this market, under a detailed SWOT framework.
Chapter 20 is a collection of interview transcripts, featuring discussions held with key stakeholders in this market. In this chapter, we have presented the details of interviews held with Mark Banister (CEO, Medipacs), Michael Hooven (CEO, Enable Injections), Jesper Roested (CEO, Subcuject), Pieter Muntendam (former President and CEO, scPharmaceuticals), Menachem Zucker (Vice President and Chief Scientist, Elcam Medical), Graham Reynolds (Former Vice President and GM, Biologics, West Pharmaceutical Services), (Vice President, Ypsomed), Eric Chappel (R&D Project Manager, Debiotech) and Mindy Katz (Vice President, Marketing and Alliance Management, Sorrel Medical)
Chapter 21 is a summary of the overall report, wherein we have mentioned all the key facts and figures described in the previous chapters.
Chapter 22 is an appendix, which provides tabulated data and numbers for all the figures included in the report.
Chapter 23 is an appendix, which provides a list of companies and organizations mentioned in this report.
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Drug Delivery Devices
3.3. Conventional Parenteral Drug Delivery Devices
3.3.1 Limitations of Conventional Parenteral Drug Delivery Devices
3.3.2 Needlestick Injuries
3.3.2.1. Incidence and Cost Burden
3.3.2.2. Prevention of Needlestick Injuries
3.3.2.3. Government Legislations for the Prevention of Needlestick Injuries
3.4. Emergence of Self-Administration Devices
3.4.1. Driving Factors
3.4.1.1. Rising Burden of Chronic Diseases
3.4.1.2. Healthcare Cost Savings
3.4.1.3. Need for Immediate Treatment in Emergency Situations
3.4.1.4. Growing Injectable Drugs Market
3.4.1.5. Need for Improving Medication Adherence
3.5. Available Self-Injection Devices
3.5.1. Prefilled Syringes
3.5.2. Pen-Injectors
3.5.3. Needle-Free Injectors
3.5.4. Autoinjectors
3.5.5. Large Volume Wearable Injectors
3.6. Regulatory Considerations
3.6.1. Medical Devices
3.6.2. Drug Device Combination Products
3.7. Future Perspectives
4. LARGE VOLUME WEARABLE INJECTORS FOR NON-INSULIN DRUGS: CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Large Volume Wearable Injectors: Overall Market Landscape
4.3. Large Volume Wearable Injectors for Non-Insulin Drugs: Market Landscape
4.3.1.1. Analysis by Status of Development
4.3.1.2. Analysis by Type of Device
4.3.1.3. Analysis by Route of Administration
4.3.1.4. Analysis by Therapeutic Area
4.3.1.5. Analysis by Type of Technology
4.3.1.6. Analysis by Type of Dose
4.3.1.7. Analysis by Mode of Injection
4.3.1.8. Analysis by Volume / Storage Capacity (in mL)
4.3.1.9. Analysis by Actuation Mechanism
4.3.1.10. Analysis by Usability
4.3.1.11. Analysis by Availability of Prefilled Drug Reservoir
4.3.1.12. Analysis by Availability of Connectivity
4.3.1.13. Analysis by Drug Compatibility
4.3.1.14. Analysis by Drug Container
4.4. Large Volume Wearable Injectors for Non-Insulin Drugs: Developer Landscape
4.4.1.1. Analysis by Year of Establishment
4.4.1.2. Analysis by Company Size
4.4.1.3. Analysis by Region of Headquarters
4.4.1.4. Analysis by Location of Headquarters
4.3.1.5. Leading Players: Analysis by Number of Products Manufactured
5. LARGE VOLUME DRUG DEVICE COMBINATIONS: CURRENT MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Large Volume Drug Device Combinations: Market Landscape
5.2.1.1. Analysis by Status of Development
5.2.1.2. Analysis by Type of Device
5.2.1.3. Analysis by Route of Administration
5.2.1.4. Analysis by Therapeutic Area
5.2.1.5. Analysis by Drug Compatibility
5.2.1.6. Analysis by Drug Container
5.2.1.7. Analysis by Type of Dose
5.2.1.8. Analysis by Mode of Injection
5.2.1.9. Analysis by Mechanism of Action
5.2.1.10. Analysis by Type of Technology
5.2.1.11. Analysis by Volume / Storage Capacity (in mL)
5.2.1.12. Analysis by Usability
5.3 Large Volume Drug Device Combinations: Developer Landscape
5.3.1.1. Analysis by Year of Establishment
5.3.1.2. Analysis by Company Size
5.3.1.3. Analysis by Location of Headquarters
5.3.1.4. Leading Players: Analysis by Number of Products Manufactured
6. LARGE VOLUME WEARABLE INJECTORS FOR INSULIN DRUGS: CURRENT MARKET LANDSCAPE
6.1. Chapter Overview
6.2. Large Volume Wearable Injectors for Insulin Drugs: Market Landscape
6.2.1.1. Analysis by Status of Development
6.2.1.2. Analysis by Type of Device
6.2.1.3. Analysis by Volume / Storage Capacity (in mL)
6.2.1.4. Analysis by Usability
6.2.1.5. Analysis by Availability of Prefilled Drug Reservoir
6.2.1.6. Analysis by Type of Dose
6.2.1.7. Analysis by Combination Insulin
6.2.1.8. Analysis by Non-Interoperable Device
6.2.1.9. Analysis by Availability of Continuous Glucose Monitoring (CGM) / Blood Glucose Meters (BGM) System
6.2.1.10. Analysis by Availability of Automated Insulin Delivery (AID) Feature
6.2.1.11. Analysis by Availability of Automatic Insulin Delivery (AID) / Artificial Pancreas
6.2.1.12. Analysis by Availability of Connectivity
6.2.1.13. Analysis by Device Control Features
6.3. Large Volume Wearable Injectors for Insulin Drugs: Developer Landscape
6.3.1.1. Analysis by Year of Establishment
6.3.1.2. Analysis by Company Size
6.3.1.3. Analysis by Location of Headquarters
6.3.1.4. Leading Players: Analysis by Number of Products Manufactured
7. PRODUCT COMPETITIVENESS ANALYSIS
7.1. Chapter Overview
7.2. Methodology
7.3. Assumptions / Key Parameters
7.4. Product Competitiveness Analysis
7.4.1. Large Volume Wearable Injectors for Non-Insulin Drugs
7.4.2. Large Volume Drug Device Combinations
7.4.3. Large Volume Wearable Injectors for Insulin Drugs
8. LARGE VOLUME WEARABLE INJECTORS: COMPANY PROFILES
8.1. Chapter Overview
8.2. Large Volume Wearable Injectors for Non-Insulin Drugs: Key Players
8.2.1. Becton Dickinson
8.2.1.1. Company Snapshot
8.2.1.2. Financial Information
8.2.1.3. Product Portfolio
8.2.1.4. Recent Developments and Future Outlook
8.2.2. Bespak
8.2.2.1. Company Snapshot
8.2.2.2. Financial Information
8.2.2.3. Product Portfolio
8.2.2.4. Recent Developments and Future Outlook
8.2.3. Enable Injections
8.2.3.1. Company Snapshot
8.2.3.2. Product Portfolio
8.2.3.3. Recent Developments and Future Outlook
8.2.4. Insulet
8.2.4.1. Company Snapshot
8.2.4.2. Financial Information
8.2.4.3. Product Portfolio
8.2.4.4. Recent Developments and Future Outlook
8.2.5. Roche
8.2.5.1. Company Snapshot
8.2.5.2. Financial Information
8.2.5.3. Product Portfolio
8.2.5.4. Recent Developments and Future Outlook
8.2.6. Sensile Medical
8.2.6.1. Company Snapshot
8.2.6.2. Product Portfolio
8.2.6.3. Recent Developments and Future Outlook
8.2.7. Sonceboz
8.2.7.1. Company Snapshot
8.2.7.2. Product Portfolio
8.2.7.3. Recent Developments and Future Outlook
8.2.8. SteadyMed Therapeutics
8.2.8.1. Company Snapshot
8.2.8.2. Product Portfolio
8.2.8.3. Recent Developments and Future Outlook
8.2.9. Weibel CDS
8.2.9.1. Company Snapshot
8.2.9.2. Product Portfolio
8.2.9.3. Recent Developments and Future Outlook
8.2.10. West Pharmaceutical Services
8.2.10.1. Company Snapshot
8.2.10.2. Financial Information
8.2.10.3. Product Portfolio
8.2.10.4. Recent Developments and Future Outlook
8.3. Large Volume Wearable Injectors for Insulin Drugs: Key Players
8.3.1. CeQur
8.3.1.1. Company Snapshot
8.3.1.2. Product Portfolio
8.3.1.3. Recent Developments and Future Outlook
8.3.2. Debiotech
8.3.2.1. Company Snapshot
8.3.2.2. Product Portfolio
8.3.2.3. Recent Developments and Future Outlook
8.3.3. Eli Lilly
8.3.3.1. Company Snapshot
8.3.3.2. Financial Information
8.3.3.3. Product Portfolio
8.3.3.4. Recent Developments and Future Outlook
8.3.4. Medtronic
8.3.4.1. Company Snapshot
8.3.4.2. Financial Information
8.3.4.3. Product Portfolio
8.3.4.4. Recent Developments and Future Outlook
8.3.5. PharmaSens
8.3.5.1. Company Snapshot
8.3.5.2. Product Portfolio
8.3.5.3. Recent Developments and Future Outlook
8.3.6. SOOIL Development
8.3.6.1. Company Snapshot
8.3.6.2. Product Portfolio
8.3.6.3. Recent Developments and Future Outlook
8.3.7. Tandem Diabetes Care
8.3.7.1. Company Snapshot
8.3.7.2. Financial Information
8.3.7.3. Product Portfolio
8.3.7.4. Recent Developments and Future Outlook
9. DRUG-DEVICE COMBINATIONS: TABULATED PROFILES
9.1. Chapter Overview
9.2. 3M™ hMTS (Adalimumab)
9.3. D-mine® Pump (Apomorphine)
9.4. ND0701 (Apomorphine)
9.5. SMT-301 (Bupivacaine)
9.6. sc2Wear® Infusor (Ceftriaxone)
9.7. 3 mL Micropump (Furosemide)
9.8. FUROSCIX® On-body Infusor (Furosemide)
9.9. Herceptin® sc Injection (Herceptin)
9.10. SMT-201(Ketorolac)
9.11. ND0612 and ND0901 (Levodopa and Carbidopa)
9.12. The LUTREPULSE® System (Lutrepulse)
9.13. Neulasta OnPro™ On-body Injector (Neulasta)
9.14. Pushtronex® System (Repatha)
9.15. ULTOMRIS® (Ravulizumab)
9.16. Trevyent® (Treprostinil)
10. PARTNERSHIPS AND COLLABORATIONS
10.1. Chapter Overview
10.2. Partnership Models
10.3. List of Partnerships and Collaborations
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partner
10.3.3. Analysis by Type of Partnership
10.3.4. Analysis by Type of Device
10.3.5. Analysis by Type of Technology
10.3.6. Analysis by Year of Partnership and Type of Partner
10.3.7. Most Active Players: Analysis by Number of Partnerships
10.3.8. Most Active Players: Analysis by Type of Partnership
10.3.9. Regional Analysis
10.3.10. Intercontinental and Intracontinental Agreements
11. KEY ACQUISITION TARGETS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Scoring Criteria and Key Assumptions
11.4. Potential Acquisition Targets for Players Offering Non-Insulin Drug Delivery Players
11.5. Potential Acquisition Targets for Players Offering Insulin Drug Delivery Players
11.6. Concluding Remarks
12. PATENT ANALYSIS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Large Volume Wearable Injectors: Patent Analysis
12.3.1. Analysis by Publication Year
12.3.2. Analysis by Issuing Authority / Patent Offices Involved
12.3.3. Analysis by CPC Symbols
12.3.4. Word Cloud Analysis: Emerging Focus Areas
12.3.5. Analysis by Type of Organization
12.3.6 Leading Industry Players: Analysis by Number of Patents
12.3.7. Leading Non-Industry Players: Analysis by Number of Patents
12.4. Large Volume Wearable Injectors: Benchmarking Patent Analysis
12.4.1. Analysis by Patent Age, 2001-2021
12.2. Large Volume Wearable Injectors: Patent Valuation Analysis
13. LARGE VOLUME WEARABLE INJECTORS: LIKELY DRUG CANDIDATES
13.1. Chapter Overview
13.2. Marketed Drugs
13.2.1. Most Likely Candidates for Delivery via Large Volume Wearable Injectors
13.2.2. Likely Candidates for Delivery via Large Volume Wearable Injectors
13.2.3. Less Likely Candidates for Delivery via Large Volume Wearable Injectors
13.2.4. Unlikely Candidates for Delivery via Large Volume Wearable Injectors
13.3. Clinical stage Drug Candidates
13.3.1. Biologics
13.3.1.1. Most Likely Candidates for Delivery via Large Volume Wearable Injectors
13.3.1.2. Likely Candidates for Delivery via Large Volume Wearable Injectors
13.3.1.3. Less Likely Candidates for Delivery via Large Volume Wearable Injectors
13.3.1.4. Unlikely Candidates for Delivery via Large Volume Wearable Injectors
13.4.2. Small Molecules
13.4.2.1. Most Likely Candidates for Delivery via Large Volume Wearable Injectors
13.4.2.2. Likely Candidates for Delivery via Large Volume Wearable Injectors
13.4.2.3. Less Likely Candidates for Delivery via Large Volume Wearable Injectors
13.4.2.4. Unlikely Candidates for Delivery via Large Volume Wearable Injectors
14. CLINICAL TRIAL ANALYSIS
14.1. Chapter Overview
14.2. Scope and Methodology
14.3. Large Volume Wearable Injectors: Clinical Trial Analysis
14.3.1. Analysis by Trial Registration Year
14.3.2. Analysis by Trial Phase
14.3.3. Analysis by Trial Recruitment Status
14.3.4. Analysis by Study Design
14.3.5. Analysis by Type of Sponsor / Collaborator
14.3.6. Most Active Players: Analysis by Number of Registered Trials
14.3.7. Word Cloud: Key Focus Areas
14.3.8. Analysis by Therapeutic Area
14.3.10. Geographical Analysis by Number of Clinical Trials
14.3.11. Geographical Analysis by Enrolled Patient Population
14.3.12. Analysis by Clinical Endpoints
15. FUNDING AND INVESTMENT ANALYSIS
15.1. Chapter Overview
15.2. Types of Funding
15.3. Large Volume Wearable Injectors: Recent Funding Instances
15.3.1. Analysis by Year of Investment
15.3.2. Analysis by Year and Amount Invested
15.3.3. Analysis by Type of Funding
15.3.4. Analysis by Year and Type of Funding
15.3.5. Analysis by Type of Funding and Amount Invested
15.3.6. Analysis by Type of Device and Amount Invested
15.3.7. Analysis by Target Disease Indication
15.3.8. Leading Players: Analysis by Number of Funding Instances
15.3.9. Leading Players: Analysis by Amount Invested
15.3.10. Most Active Investors: Analysis by Number of Instances
15.3.11. Analysis by Geography
16. CASE STUDY: ROLE OF CONTRACT MANUFACTURING ORGANIZATIONS IN DEVICE DEVELOPMENT SUPPLY CHAIN
16.1. Chapter Overview
16.2. Device Development Supply Chain
16.3. Role of Contract Manufacturing Organizations (CMOs) in Device Development
16.4. List of CMOs
16.4.1. Contract Manufacturers: Geographical Distribution and Services Offered
16.5 Medical Device: Product Design and Development
17. REGULATORY AND REIMBURSEMENT LANDSCAPE FOR MEDICAL DEVICES
17.1. Chapter Overview
17.2. General Regulatory and Reimbursement Guidelines for Medical Devices
17.3. Regulatory and Reimbursement Landscape in North America
17.3.1. The US Scenario
17.3.1.1. Regulatory Authority
17.3.1.2. Review / Approval Process
17.3.1.3. Reimbursement Landscape
17.3.1.3.1. Payer Mix
17.3.1.3.2. Reimbursement Process
17.3.2. The Canadian Scenario
17.3.2.1. Regulatory Authority
17.3.2.2. Review / Approval Process
17.3.2.3. Reimbursement Landscape
17.3.2.3.1. Payer Mix
17.3.2.3.2. Reimbursement Process
17.3.3. The Mexican Scenario
17.3.3.1. Regulatory Authority
17.3.3.2. Review / Approval Process
17.3.3.3. Reimbursement Landscape
17.3.3.3.1. Payer Mix
17.4. Regulatory and Reimbursement Landscape in Europe
17.4.1. Overall Scenario
17.4.1.1. Overall Regulatory Authority
17.4.1.2. Overall Review / Approval Process
17.4.2. The UK Scenario
17.4.2.1. Regulatory Authority
17.4.2.2. Review / Approval Process
17.4.2.3. Reimbursement Landscape
17.4.2.3.1. Payer Mix
17.4.2.3.2. Reimbursement Process
17.4.3. The French Scenario
17.4.3.1. Regulatory Authority
17.4.3.2. Review / Approval Process
17.4.3.3. Reimbursement Landscape
17.4.3.3.1. Payer Mix
17.4.3.3.2. Reimbursement Process
17.4.4. The German Scenario
17.4.4.1. Regulatory Authority
17.4.4.2. Review / Approval Process
17.4.4.3. Reimbursement Landscape
17.4.4.3.1. Payer Mix
17.4.4.3.2. Reimbursement Process
17.4.5. The Italian Scenario
17.4.5.1. Regulatory Authority
17.4.5.2. Review / Approval Process
17.4.5.3. Reimbursement Landscape
17.4.5.3.1. Payer Mix
17.4.5.3.2. Reimbursement Process
17.4.6. The Spanish Scenario
17.4.6.1. Regulatory Authority
17.4.6.2. Review / Approval Process
17.4.6.3. Reimbursement Landscape
17.4.6.3.1. Payer Mix
17.4.6.3.2. Reimbursement Process
17.5. Regulatory and Reimbursement Landscape in Asia-Pacific and Rest of the World
17.5.1. The Australian Scenario
17.5.1.1. Regulatory Authority
17.5.1.2. Review / Approval Process
17.5.1.3. Reimbursement Landscape
17.5.1.3.1. Payer Mix
17.5.1.3.2. Reimbursement Process
17.5.2. The Brazilian Scenario
17.5.2.1. Regulatory Authority
17.5.2.2. Review / Approval Process
17.5.2.3. Reimbursement Landscape
17.5.2.3.1. Payer Mix
17.5.2.3.2. Reimbursement Process
17.5.3. The Chinese Scenario
17.5.3.1. Regulatory Authority
17.5.3.2. Review / Approval Process
17.5.3.3. Reimbursement Landscape
17.5.3.3.1. Payer Mix
17.5.3.3.2. Reimbursement Process
17.5.4. The Indian Scenario
17.5.4.1. Regulatory Authority
17.5.4.2. Review / Approval Process
17.5.4.3. Reimbursement Landscape
17.5.4.3.1. Payer Mix
17.5.5. The Israeli Scenario
17.5.5.1. Regulatory Authority
17.5.5.2. Review / Approval Process
17.5.5.3. Reimbursement Landscape
17.5.5.3.1. Payer Mix
17.5.6. The Japanese Scenario
17.5.6.1. Regulatory Authority
17.5.6.2. Review / Approval Process
17.5.6.3. Reimbursement Landscape
17.5.6.3.1. Payer Mix
17.5.6.3.2. Reimbursement Process
17.5.7. The New Zealand Scenario
17.5.7.1. Regulatory Authority
17.5.7.2. Review / Approval Process
17.5.7.3. Reimbursement Landscape
17.5.7.3.1. Payer Mix
17.5.7.3.2. Reimbursement Process
17.5.8. The Singaporean Scenario
17.5.8.1. Regulatory Authority
17.5.8.2. Review / Approval Process
17.5.8.3. Reimbursement Landscape
17.5.8.3.1. Payer Mix
17.5.8.3.2. Reimbursement Process
17.5.9. The South Korea Scenario
17.5.9.1. Regulatory Authority
17.5.9.2. Review / Approval Process
17.5.9.3. Reimbursement Landscape
17.5.9.3.1. Payer Mix
17.5.9.3.2. Reimbursement Process
17.5.10. The South African Scenario
17.5.10.1. Regulatory Authority
17.5.10.2. Review / Approval Process
17.5.10.3. Reimbursement Landscape
17.5.11. The Taiwanese Scenario
17.5.11.1. Regulatory Authority
17.5.11.2. Review / Approval Process
17.5.11.3. Reimbursement Landscape
17.5.11.3.1. Payer Mix
17.5.11.3.2. Reimbursement Process
17.5.12. The Thailand Scenario
17.5.12.1. Regulatory Authority
17.5.12.2. Review / Approval Process
17.5.12.3. Reimbursement Landscape
17.6. Comparison of Regional Regulatory Environment
17.7. Concluding Remarks
18. MARKET SIZING AND OPPORTUNITY ANALYSIS
18.1. Chapter Overview
18.2. Forecast Methodology and Key Assumptions
18.3. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, 2021-2035 (By Value)
18.3.1. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device, 2021-2035 (By Value)
18.3.2 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability, 2021-2035 (By Value)
18.3.3 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area, 2021-2035 (By Value)
18.4 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, 2021-2035 (By Value)
18.4.1 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Type of Device, 2021-2035 (By Value)
18.4.2 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Usability, 2021-2035 (By Value)
18.4.3 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Therapeutic Area, 2021-2035 (By Value)
18.5 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, 2021-2035 (By Value)
18.5.1 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Type of Device, 2021-2035 (By Value)
18.5.2 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Usability, 2021-2035 (By Value)
18.5.3 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Therapeutic Area, 2021-2035 (By Value)
18.6 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific, 2021-2035 (By Value)
18.6.1 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Type of Device, 2021-2035 (By Value)
18.6.2 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Usability, 2021-2035 (By Value)
18.6.3 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Therapeutic Area, 2021-2035 (By Value)
18.7 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America, 2021-2035 (By Value)
18.7.1 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America: Distribution by Type of Device, 2021-2035 (By Value)
18.7.2 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America: Distribution by Usability, 2021-2035 (By Value)
18.7.3 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America: Distribution by Therapeutic Area, 2021-2035 (By Value)
18.8 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, 2021-2035 (By Value)
18.8.1 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Type of Device, 2021-2035 (By Value)
18.8.2 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Usability, 2021-2035 (By Value)
18.8.3 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Therapeutic Area, 2021-2035 (By Value)
18.9. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, 2021-2035 (By Volume)
18.9.1. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device, 2021-2035 (By Volume)
18.9.2 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability, 2021-2035 (By Volume)
18.9.3 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area, 2021-2035 (By Volume)
18.1 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, 2021-2035 (By Volume)
18.10.1 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Type of Device, 2021-2035 (By Volume)
18.10.2 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Usability, 2021-2035 (By Volume)
18.10.3 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Therapeutic Area, 2021-2035 (By Volume)
18.11 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, 2021-2035 (By Volume)
18.11.1 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Type of Device, 2021-2035 (By Volume)
18.11.2 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Usability, 2021-2035 (By Volume)
18.11.3 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Therapeutic Area, 2021-2035 (By Volume)
18.12 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific, 2021-2035 (By Value)
18.12.1 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Type of Device, 2021-2035 (By Value)
18.12.2 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Usability, 2021-2035 (By Value)
18.12.3 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Therapeutic Area, 2021-2035 (By Value)
18.13 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America, 2021-2035 (By Value)
18.13.1 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America: Distribution by Type of Device, 2021-2035 (By Value)
18.13.2 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America: Distribution by Usability, 2021-2035 (By Value)
18.13.3 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America: Distribution by Therapeutic Area, 2021-2035 (By Value)
18.14 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, 2021-2035 (By Value)
18.14.1 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Type of Device, 2021-2035 (By Value)
18.14.2 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Usability, 2021-2035 (By Value)
18.14.3 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Therapeutic Area, 2021-2035 (By Value)
18.15. Global Large Volume Wearable Injectors Market for Insulin, 2021-2035
18.15.1 Global Large Volume Wearable Injectors Market for Insulin: Distribution by Type of Device, 2021-2035
18.15.2 Global Large Volume Wearable Injectors Market for Insulin: Distribution by Usability, 2021-2035
18.16 Large Volume Wearable Injectors Market for Insulin in North America, 2021-2035
18.16.1 Large Volume Wearable Injectors Market for Insulin in North America: Distribution by Type of Device, 2021-2035
18.16.2 Large Volume Wearable Injectors Market for Insulin in North America: Distribution by Usability, 2021-2035
18.17 Large Volume Wearable Injectors Market for Insulin in Europe, 2021-2035
18.17.1 Large Volume Wearable Injectors Market for Insulin in Europe: Distribution by Type of Device, 2021-2035
18.17.2 Large Volume Wearable Injectors Market for Insulin in Europe: Distribution by Usability, 2021-2035
18.18 Large Volume Wearable Injectors Market for Insulin in Asia Pacific, 2021-2035
18.18.1 Large Volume Wearable Injectors Market for Insulin in Asia Pacific: Distribution by Type of Device, 2021-2035
18.18.2 Large Volume Wearable Injectors Market for Insulin in Asia Pacific: Distribution by Usability, 2021-2035
18.19 Large Volume Wearable Injectors Market for Insulin in Latin America, 2021-2035
18.19.1 Large Volume Wearable Injectors Market for Insulin in Latin America: Distribution by Type of Device, 2021-2035
18.19.2 Large Volume Wearable Injectors Market for Insulin in Latin America: Distribution by Usability, 2021-2035
18.2 Large Volume Wearable Injectors Market for Insulin in Middle East and North Africa, 2021-2035
18.20.1 Large Volume Wearable Injectors Market for Insulin in Middle East and North Africa: Distribution by Type of Device, 2021-2035
18.20.2 Large Volume Wearable Injectors Market for Insulin in Middle East and North Africa: Distribution by Usability, 2021-2035
19. SWOT ANALYSIS
19.1. Chapter Overview
19.2. SWOT Analysis
19.2.1. Strengths
19.2.2. Weaknesses
19.2.3. Opportunities
19.2.4. Threats
19.3. Large Volume Wearable Injectors: Future Growth Opportunities
19.3.1. Rising Focus on Self-Administration of Drugs
19.3.2. Possibility of Integration with Mobile Applications
19.3.3. Potential Life Cycle Management Tool
19.3.4. Potential Usability for Multiple Therapeutic Areas
20. EXECUTIVE INSIGHTS
20.1. Chapter Overview
20.2. Medipacs
20.2.1. Company Snapshot
20.2.2. Interview Transcript: Mark Banister, Chief Executive Officer
20.3. Enable Injections
20.3.1. Company Snapshot
20.3.2. Interview Transcript: Michael Hooven, Chief Executive Officer
20.4. Subcuject
20.4.1. Company Snapshot
20.4.2. Interview Transcript: Jesper Roested, Chief Executive Officer
20.5. scPharmaceuticals
20.5.1. Company Snapshot
20.5.2. Interview Transcript: Pieter Muntendam, former President and Chief Executive Officer
20.6. Elcam Medical
20.6.1. Company Snapshot
20.6.2. Interview Transcript: Menachem Zucker, Vice President and Chief Scientist
20.7. West Pharmaceutical Services
20.7.1. Company Snapshot
20.7.2. Interview Transcript: Graham Reynolds, Former Vice President and General Manager, Biologics
20.8. Ypsomed
20.8.1. Company Snapshot
20.8.2. Interview Transcript: Vice President
20.9. Debiotech
20.9.1. Company Snapshot
20.9.2. Interview Transcript: Eric Chappel, R&D Project Manager
20.10. Sorrel Medical
20.10.1. Company Snapshot
20.10.2. Interview Transcript: Mindy Katz, Vice President, Marketing and Alliance Management
21. CONCLUDING REMARKS
22. APPENDIX 1: TABULATED DATA
23. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 2.1 Executive Summary: Market Forecast
Figure 2.2 Executive Summary: Market Landscape of Large Volume Wearable Injectors for Non-Insulin Drugs
Figure 2.3 Executive Summary: Market Landscape of Large Volume Drug Device Combinations
Figure 2.4 Executive Summary: Market Landscape of Large Volume Wearable Injectors for Insulin Drugs
Figure 2.5 Executive Summary: Partnerships and Collaborations
Figure 2.6 Executive Summary: Key Acquisition Targets
Figure 2.7 Executive Summary: Patent Analysis
Figure 2.8 Executive Summary: Likely Drug Candidates
Figure 2.9 Executive Summary: Clinical Trial Analysis
Figure 2.10 Executive Summary: Funding and Investment Analysis
Figure 3.1 Popular Drug Delivery Systems
Figure 3.2 Evolution of Healthcare Safety Legislations
Figure 3.3 Large Volume Wearable Injectors Market: Driving Factors
Figure 3.4 Types of Self-Injection Devices
Figure 4.1 Large Volume Wearable Injectors: Overall Market Landscape
Figure 4.2 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Status of Development
Figure 4.3 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Device
Figure 4.4 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Route of Administration
Figure 4.5 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Therapeutic area
Figure 4.6 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Technology
Figure 4.7 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Dose
Figure 4.8 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Mode of Injection
Figure 4.9 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Volume / Storage Capacity (in mL)
Figure 4.10 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Actuation Mechanism
Figure 4.11 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Usability
Figure 4.12 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Availability of Prefilled Drug Reservoir
Figure 4.13 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Connectivity
Figure 4.14 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Drug Compatibility
Figure 4.15 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Drug Container
Figure 4.16 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution of Developers by Year of Establishment
Figure 4.17 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution of Developers by Company Size
Figure 4.18 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution of Developers by Region of Headquarters
Figure 4.19 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution of Developers by Location of Headquarters
Figure 4.20 Leading Players: Distribution by Number of Products Manufactured
Figure 5.1 Large Volume Drug Device Combinations: Distribution by Status of Development
Figure 5.2 Large Volume Drug Device Combinations: Distribution by Type of Device
Figure 5.3 Large Volume Drug Device Combinations: Distribution by Route of Administration
Figure 5.4 Large Volume Drug Device Combinations: Distribution by Therapeutic Area
Figure 5.5 Large Volume Drug Device Combinations: Distribution by Drug Compatibility
Figure 5.6 Large Volume Drug Device Combinations: Distribution by Drug Container
Figure 5.7 Large Volume Drug Device Combinations: Distribution by Type of Dose
Figure 5.8 Large Volume Drug Device Combinations: Distribution by Mode of Injection
Figure 5.9 Large Volume Drug Device Combinations: Distribution by Mechanism of Action
Figure 5.10 Large Volume Drug Device Combinations: Distribution by Type of Technology
Figure 5.11 Large Volume Drug Device Combinations: Distribution by Volume / Storage Capacity (in mL)
Figure 5.12 Large Volume Drug Device Combinations: Distribution by Usability
Figure 5.13 Large Volume Wearable Injectors for Drug Device Combinations: Distribution of Developers by Year of Establishment
Figure 5.14 Large Volume Wearable Injectors for Drug Device Combinations: Distribution of Developers by Company Size
Figure 5.15 Large Volume Wearable Injectors for Drug Device Combinations: Distribution of Developers by Location of Headquarters
Figure 5.16 Leading Players: Analysis by Number of Drug Device Combination Products Manufactured
Figure 6.1 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Status of Development
Figure 6.2 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Type of Device
Figure 6.3 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Volume / Storage Capacity (in mL)
Figure 6.4 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Usability
Figure 6.5 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Prefilled Drug Reservoir
Figure 6.6 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Type of Dose
Figure 6.7 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Combination Insulin
Figure 6.8 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Non-Interoperable Device
Figure 6.9 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Availability of Continuous Glucose Monitoring (CGM) / Blood Glucose Meters (BGM) System
Figure 6.10 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Automated Insulin Delivery (AID) Feature
Figure 6.11 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Availability of Automatic Insulin Delivery (AID) / Artificial Pancreas
Figure 6.12 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Availability of Connectivity
Figure 6.13 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Device Control Features
Figure 6.14 Large Volume Wearable Injectors for Insulin Drugs: Distribution of Developers by Year of Establishment
Figure 6.15 Large Volume Wearable Injectors for Insulin Drugs: Distribution of Developers by Company Size
Figure 6.16 Large Volume Wearable Injectors for Insulin: Distribution of Developers by Location of Headquarters
Figure 6.17 Leading Players: Analysis by Number of Insulin Drugs Products Manufactured
Figure 7.1 Product Competitiveness Analysis: Large Volume Wearable Injectors for Non-Insulin Drugs
Figure 7.2 Product Competitiveness Analysis: Drug Device Combinations
Figure 7.3 Product Competitiveness Analysis: Large Volume Wearable Injectors for Insulin Drugs
Figure 8.1 Becton Dickinson: Annual Revenues, 2016- H1 2021 (USD Billion)
Figure 8.2 Bespak: Annual Revenues, 2015- 2019 (GBP Million)
Figure 8.3 Insulet: Annual Revenues, 2016-H1 2021 (USD Million)
Figure 8.4 Roche: Annual Revenues, 2016-Q1 2021 (CHF Billion)
Figure 8.5 West Pharmaceutical Services: Annual Revenues, 2016- H1 2021 (USD Billion)
Figure 8.6 Eli Lilly: Annual Revenues, 2016- H1 2021 (USD Billion)
Figure 8.7 Medtronic: Annual Revenues, 2016-Q1 2021 (USD Billion)
Figure 8.8 Tandem Diabetes Care: Annual Revenues, 2016- H1 2021 (USD Million)
Figure 10.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partner
Figure 10.3 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 10.4 Partnerships and Collaborations: Distribution by Type of Device
Figure 10.5 Partnerships and Collaborations: Distribution by Type of Technology
Figure 10.6 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Figure 10.7 Most Active Players: Distribution by Number of Partnership
Figure 10.8 Most Active Players: Distribution by Type of Partnership
Figure 10.9 Partnerships and Collaborations: Regional Distribution
Figure 10.10 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 12.1 Patent Analysis: Distribution by Type of Patent
Figure 12.2 Patent Analysis: Distribution by Publication Year
Figure 12.3 Patent Analysis: Distribution by Issuing Authority / Patent Offices Involved
Figure 12.4 Patent Analysis: Distribution by CPC Symbols
Figure 12.5 Word Cloud: Emerging Focus Areas
Figure 12.6 Patent Analysis: Cumulative Distribution by Type of Organization
Figure 12.7 Leading Industry Players: Distribution by Number of Patents
Figure 12.8 Leading Non-Industry Players: Distribution by Number of Patents
Figure 12.9 Patent Analysis: Leading Individual Assignees
Figure 12.10 Leading Industry Players: Benchmarking by Patent Characteristics (CPC Symbols)
Figure 12.11 Patent Analysis: Distribution of Patents by Age, 2001-2021
Figure 12.12 Large Volume Wearable Injectors: Patent Valuation
Figure 14.1 Clinical Trial Analysis: Scope and Methodology
Figure 14.2 Clinical Trial Analysis: Distribution by Trial Registration Year
Figure 14.3 Clinical Trial Analysis: Distribution by Trial Phase
Figure 14.4 Clinical Trial Analysis: Distribution by Study Design
Figure 14.5 Clinical Trial Analysis: Distribution by Number of Registered Trials
Figure 14.6 World: Key Focus Area
Figure 14.7 Clinical Trial Analysis: Distribution by Therapeutic area
Figure 14.8 Clinical Trial Analysis: Geographical Distribution by Number of Clinical Trials
Figure 14.9 Clinical Trial Analysis: Geographical Distribution by Number of Patients Enrolled
Figure 14.10 Clinical Trial Analysis: Distribution by Clinical Endpoints
Figure 15.1 Funding and Investments: Distribution by Year of Investment
Figure 15.2 Funding and Investments: Distribution by Year and Amount Invested
Figure 15.3 Funding and Investments: Distribution by Type of Funding
Figure 15.4 Funding and Investments: Distribution by Year and Type of Funding
Figure 15.5 Funding and Investments: Distribution by Type of Funding and Amount Invested
Figure 15.6 Funding and Investments: Distribution by Type of Device and Amount Invested
Figure 15.7 Funding and Investments: Distribution by Target Disease Indication
Figure 15.8 Most Active Players: Distribution by Number of Funding Instances
Figure 15.9 Most Active Players: Distribution by Amount Invested
Figure 15.10 Most Active Investors: Distribution by Number of Instances
Figure 15.11 Funding and Investments: Distribution by Geography
Figure 16.1 CMOs for Large Volume Wearable Injectors: Market Landscape and Services Offered
Figure 17.1 Key Regulatory Authorities for Medical Devices
Figure 17.2 Medical Devices Review / Approval Process in the US
Figure 17.3 Healthcare Insurance Coverage in the US: Distribution by Type of Coverage
Figure 17.4 Medical Devices National Coverage Determination Process: US
Figure 17.5 Medical Devices Review / Approval Process in Canada
Figure 17.6 Healthcare Insurance Coverage in Canada: Distribution by Type of Coverage
Figure 17.7 Medical Devices Review / Approval Process in Mexico
Figure 17.8 Regulatory Bodies in EU5 Countries
Figure 17.9 Steps involved in CE Marking Process
Figure 17.10 Medical Devices Review / Approval Process in Europe
Figure 17.11 Medical Devices Review / Approval Process in UK
Figure 17.12 Healthcare Insurance Coverage in the UK: Distribution by Type of Coverage
Figure 17.13 Medical Devices Reimbursement Process: UK
Figure 17.14 Healthcare Insurance Coverage in France: Distribution by Type of Coverage
Figure 17.15 Medical Devices Reimbursement Process: France
Figure 17.16 Healthcare Insurance Coverage in Germany: Distribution by Type of Coverage
Figure 17.17 Medical Devices Reimbursement Process for In-Patient Setting: Germany
Figure 17.18 Medical Devices Reimbursement Process for Out-Patient Care: Germany
Figure 17.19 Healthcare Insurance Coverage in Italy: Distribution by Type of Coverage
Figure 17.20 Medical Devices Reimbursement Process: Italy
Figure 17.21 Healthcare Insurance Coverage in Spain: Distribution by Type of Coverage
Figure 17.22 Medical Devices Reimbursement Process: Spain
Figure 17.23 Medical Devices Review / Approval Process in Australia
Figure 17.24 Healthcare Insurance Coverage in Australia: Percentage Distribution by Type of Coverage
Figure 17.25 Medical Devices Review / Approval Process in Brazil
Figure 17.26 Medical Devices Reimbursement Process: Brazil
Figure 17.27 Medical Devices Review / Approval Process in China
Figure 17.28 Healthcare Insurance Coverage in China: Percentage Distribution by Type of Coverage
Figure 17.29 Medical Devices Reimbursement Process: Shanghai
Figure 17.30 Medical Devices Review / Approval Process in India
Figure 17.31 Healthcare Insurance Coverage in Israel: Percentage Distribution by Type of Coverage
Figure 17.32 Medical Devices Review / Approval Process in Japan
Figure 17.33 Medical Devices Reimbursement Process: Japan
Figure 17.34 Healthcare Insurance Coverage in Japan: Percentage Distribution by Type of Coverage
Figure 17.35 New Medical Devices Reimbursement Process: Japan
Figure 17.36 Medical Devices Review / Approval Process in New Zealand
Figure 17.37 Healthcare Insurance Coverage in New Zealand: Percentage Distribution by Type of Coverage
Figure 17.38 Medical Devices Review / Approval Process in Singapore
Figure 17.39 Medical Devices Review / Approval Process in South Korea
Figure 17.40 Healthcare Insurance Coverage in South Korea: Percentage Distribution by Type of Coverage
Figure 17.41 Medical Devices Review / Approval Process in South Africa
Figure 17.42 Medical Devices Review / Approval Process in Taiwan
Figure 17.43 Healthcare Insurance Coverage in Taiwan: Percentage Distribution by Type of Coverage
Figure 17.44 Medical Devices Review / Approval Process in Thailand
Figure 17.45 Heat Map Analysis: Comparison of Regional Regulatory Control for Medical Devices
Figure 17.46 Regulatory Control for Medical Devices: Regional Analysis by Device Risk Category
Figure 18.1 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, 2021-2035 (By Value)
Figure 18.2 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device, 2021-2035 (By Value)
Figure 18.3 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability, 2021-2035 (By Value)
Figure 18.4 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area, 2021-2035 (By Value)
Figure 18.5 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, 2021-2035 (By Value)
Figure 18.6 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Type of Device, 2021-2035 (By Value)
Figure 18.7 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Usability, 2021-2035 (By Value)
Figure 18.8 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Therapeutic Area, 2021-2035 (By Value)
Figure 18.9 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, 2021-2035 (By Value)
Figure 18.10 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Type of Device, 2021-2035 (By Value)
Figure 18.11 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Usability, 2021-2035 (By Value)
Figure 18.12 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Therapeutic Area, 2021-2035 (By Value)
Figure 18.13 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific, 2021-2035 (By Value)
Figure 18.14 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Type of Device, 2021-2035 (By Value)
Figure 18.15 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Usability, 2021-2035 (By Value)
Figure 18.16 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Therapeutic Area, 2021-2035 (By Value)
Figure 18.17 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America, 2021-2035 (By Value)
Figure 18.18 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America: Distribution by Type of Device, 2021-2035 (By Value)
Figure 18.19 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America: Distribution by Usability, 2021-2035 (By Value)
Figure 18.20 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America: Distribution by Therapeutic Area, 2021-2035 (By Value)
Figure 18.21 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, 2021-2035 (By Value)
Figure 18.22 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Type of Device, 2021-2035 (By Value)
Figure 18.23 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Usability, 2021-2035 (By Value)
Figure 18.24 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Therapeutic Area, 2021-2035 (By Value)
Figure 18.25 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, 2021-2035 (By Volume)
Figure 18.26 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device, 2021-2035 (By Volume)
Figure 18.27 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability, 2021-2035 (By Volume)
Figure 18.28 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area, 2021-2035 (By Volume)
Figure 18.29 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, 2021-2035 (By Volume)
Figure 18.30 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Type of Device, 2021-2035 (By Volume)
Figure 18.31 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Usability, 2021-2035 (By Volume)
Figure 18.32 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Therapeutic Area, 2021-2035 (By Volume)
Figure 18.33 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, 2021-2035 (By Volume)
Figure 18.34 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Type of Device, 2021-2035 (By Volume)
Figure 18.35 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Usability, 2021-2035 (By Volume)
Figure 18.36 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Therapeutic Area, 2021-2035 (By Volume)
Figure 18.37 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific, 2021-2035 (By Volume)
Figure 18.38 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Type of Device, 2021-2035 (By Volume)
Figure 18.39 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Usability, 2021-2035 (By Volume)
Figure 18.40 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Therapeutic Area, 2021-2035 (By Volume)
Figure 18.41 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America, 2021-2035 (By Volume)
Figure 18.42 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America: Distribution by Type of Device, 2021-2035 (By Volume)
Figure 18.43 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America: Distribution by Usability, 2021-2035 (By Volume)
Figure 18.44 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America: Distribution by Therapeutic Area, 2021-2035 (By Volume)
Figure 18.45 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, 2021-2035 (By Volume)
Figure 18.46 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Type of Device, 2021-2035 (By Volume)
Figure 18.47 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Usability, 2021-2035 (By Volume)
Figure 18.48 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Therapeutic Area, 2021-2035 (By Volume)
Figure 18.49 Global Large Volume Wearable Injectors Market for Insulin, 2021-2035
Figure 18.50 Global Large Volume Wearable Injectors Market for Insulin: Distribution by Type of Device, 2021-2035
Figure 18.51 Global Large Volume Wearable Injectors Market for Insulin: Distribution by Usability, 2021-2035
Figure 18.52 Large Volume Wearable Injectors Market for Insulin in North America, 2021-2035
Figure 18.53 Large Volume Wearable Injectors Market for Insulin in North America: Distribution by Type of Device, 2021-2035
Figure 18.54 Large Volume Wearable Injectors Market for Insulin in North America: Distribution by Usability, 2021-2035
Figure 18.55 Large Volume Wearable Injectors Market for Insulin in Europe, 2021-2035
Figure 18.56 Large Volume Wearable Injectors Market for Insulin in Europe: Distribution by Type of Device, 2021-2035
Figure 18.57 Large Volume Wearable Injectors Market for Insulin in Europe: Distribution by Usability, 2021-2035
Figure 18.58 Large Volume Wearable Injectors Market for Insulin in Asia Pacific, 2021-2035
Figure 18.59 Large Volume Wearable Injectors Market for Insulin in Asia Pacific: Distribution by Type of Device, 2021-2035
Figure 18.60 Large Volume Wearable Injectors Market for Insulin in Asia Pacific: Distribution by Usability, 2021-2035
Figure 18.61 Large Volume Wearable Injectors Market for Insulin in Latin America, 2021-2035
Figure 18.62 Large Volume Wearable Injectors Market for Insulin in Latin America: Distribution by Type of Device, 2021-2035
Figure 18.63 Large Volume Wearable Injectors Market for Insulin in Latin America: Distribution by Usability, 2021-2035
Figure 18.64 Large Volume Wearable Injectors Market for Insulin in Middle East and North Africa, 2021-2035
Figure 18.65 Large Volume Wearable Injectors Market for Insulin in Middle East and North Africa: Distribution by Type of Device, 2021-2035
Figure 18.66 Large Volume Wearable Injectors Market for Insulin in Middle East and North Africa: Distribution by Usability, 2021-2035
Figure 19.1 SWOT Factors: Harvey Ball Analysis
Figure 21.1 Concluding Remarks: Market Landscape of Large Volume Wearable Injectors for Non-Insulin Drugs
Figure 21.2 Concluding Remarks: Market Landscape of Large Volume Drug Device Combinations
Figure 21.3 Concluding Remarks: Market Landscape of Large Volume Wearable Injectors for Insulin Drugs
Figure 21.4 Concluding Remarks: Partnerships and Collaborations
Figure 21.5 Concluding Remarks: Key Acquisition Targets
Figure 21.6 Concluding Remarks: Patent Analysis
Figure 21.7 Concluding Remarks: Likely Drug Candidates
Figure 21.8 Concluding Remarks: Clinical Trial Analysis
Figure 21.9 Concluding Remarks: Funding and Investment Analysis
Figure 21.10 Concluding Remarks: Market Forecast
Table 3.1 List of Prefilled Syringes
Table 3.2 List of Pen-Injector Systems
Table 3.3 List of Autoinjector Systems
Table 3.4 List of Needle-Free Injectors
Table 4.1 Large Volume Wearable Injectors for Non-Insulin Drugs: Information on Development Status and Device Features
Table 4.2 Large Volume Wearable Injectors for Non-Insulin Drugs: Information on Administration Related Parameters
Table 4.3 Large Volume Drug Device Combinations for Non-Insulin Drugs: Information on Developers
Table 5.1 Large Volume Drug Device Combinations: Information on Development Status and Device Features
Table 5.2 Large Volume Drug Device Combinations: Information on Drug Administration Related Parameters
Table 5.3 Large Volume Wearable Injectors for Drug Device Combinations: Information on Developers
Table 6.1 Large Volume Wearable Injectors for Insulin Drugs: Information on Development Status and Device Features
Table 6.2 Large Volume Wearable Injectors for Insulin Drugs: Information on Administration Related Parameters
Table 6.3 Large Volume Drug Device Combinations for Insulin Drugs: Information on Developers
Table 8.1 Large Volume Wearable Injectors: List of Companies Profiled
Table 8.2 Becton Dickinson: Product Portfolio
Table 8.3 Becton Dickinson: Recent Developments and Future Outlook
Table 8.4 Bespak: Recent Developments and Future Outlook
Table 8.5 Enable Injections: Recent Developments and Future Outlook
Table 8.6 Insulet: Recent Developments and Future Outlook
Table 8.7 Roche: Recent Developments and Future Outlook
Table 8.8 Sensile Medical: Product Portfolio
Table 8.9 Sensile Medical: Recent Developments and Future Outlook
Table 8.10 Sonceboz: Product Portfolio
Table 8.11 Sonceboz: Recent Developments and Future Outlook
Table 8.12 SteadyMed Therapeutics: Product Portfolio
Table 8.13 SteadyMed Therapeutics: Recent Developments and Future Outlook
Table 8.14 Weibel CDS: Product Portfolio
Table 8.15 Weibel CDS: Recent Developments and Future Outlook
Table 8.16 West Pharmaceutical Services: Product Portfolio
Table 8.17 West Pharmaceutical Services: Recent Developments and Future Outlook
Table 8.18 CeQur: Recent Developments and Future Outlook
Table 8.19 Debiotech: Product Portfolio
Table 8.20 Debiotech: Recent Developments and Future Outlook
Table 8.21 Eli Lilly: Recent Developments and Future Outlook
Table 8.22 Medtronic: Recent Developments and Future Outlook
Table 8.23 SOOIL Development: Recent Developments and Future Outlook
Table 8.24 Tandem Diabetes Care: Technology Portfolio
Table 8.25 Tandem Diabetes Care: Features of slim X2 Insulin Pump
Table 8.26 Tandem Diabetes Care: Recent Developments and Future Outlook
Table 9.1 Large Volume Drug Device Combination: 3M™ hMTS (Adalimumab)
Table 9.2 Large Volume Drug Device Combination: D-mine® Pump (Apomorphine)
Table 9.3 Large Volume Drug Device Combination: ND0701 (Apomorphine)
Table 9.4 Large Volume Drug Device Combination: SMT-301 (Bupivacaine)
Table 9.5 Large Volume Drug Device Combination: sc2Wear® Infusor (Ceftriaxone)
Table 9.6 Large Volume Drug Device Combination: 3 mL Micropump (Furosemide)
Table 9.7 Large Volume Drug Device Combination: FUROSCIX® On-body Infusor (Furosemide)
Table 9.8 Large Volume Drug Device Combination: Herceptin® sc Injection (Herceptin)
Table 9.9 Large Volume Drug Device Combination: SMT-201(Ketorolac)
Table 9.10 Large Volume Drug Device Combination: ND0612 and ND0901 (Levodopa and Carbidopa)
Table 9.11 Large Volume Drug Device Combination: The LUTREPULSE® System (Lutrepulse)
Table 9.12 Large Volume Drug Device Combination: Neulasta OnPro™ On-body Injector (Neulasta)
Table 9.13 Large Volume Drug Device Combination: Pushtronex® System (Repatha)
Table 9.14 Large Volume Drug Device Combination: ULTOMRIS® (Ravulizumab)
Table 9.15 Large Volume Drug Device Combination: Trevyent® (Treprostinil)
Table 10.1 Large Volume Wearable Injectors: List of Partnerships and Collaborations, 2015-2021
Table 11.1 Non-Insulin Drug Delivery Devices: Likelihood of Players for Acquisition
Table 11.2 Insulin Delivery Devices: Likelihood of Players for Acquisition
Table 12.1 Patent Analysis: Prominent CPC Symbols
Table 12.2 Patent Analysis: List of Top CPC Symbols
Table 12.3 Patent Analysis: Most Popular CPC Symbols
Table 12.4 Patent Analysis: Summary of Benchmarking Analysis
Table 12.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 12.6 Patent Analysis: List of Leading Patents (by Highest Relative Valuation)
Table 13.1 Marketed Molecules: Most Likely Candidates for Delivery via Large Volume Wearable Injectors
Table 13.2 Marketed Molecules: Likely Candidates for Delivery via Large Volume Wearable Injectors
Table 13.3 Marketed Molecules: Less Likely Candidates for Delivery via Large Volume Wearable Injectors
Table 13.4 Marketed Molecules: Unlikely Candidates for Delivery via Large Volume Wearable Injectors
Table 13.5 Clinical Drug Candidates (Biologics): Most Likely Candidates for Delivery via Large Volume Wearable Injectors
Table 13.6 Clinical Drug Candidates (Biologics): Likely Candidates for Delivery via Large Volume Wearable Injectors
Table 13.7 Clinical Drug Candidates (Biologics): Less Likely Candidates for Delivery via Large Volume Wearable Injectors
Table 13.8 Clinical Drug Candidates (Biologics): Unlikely Candidates for Delivery via Large Volume Wearable Injectors
Table 13.9 Clinical Drug Candidates (Small Molecules): Most Likely Candidates for Delivery via Large Volume Wearable Injectors
Table 13.10 Clinical Drug Candidates (Small Molecules): Likely Candidates for Delivery via Large Volume Wearable Injectors
Table 13.11 Clinical Drug Candidates (Small Molecules): Less Likely Candidates for Delivery via Large Volume Wearable Injectors
Table 13.12 Clinical Drug Candidates (Small Molecules): Unlikely Candidates for Delivery via Large Volume Wearable Injectors
Table 15.1 List of Funding Instances, 2014-2021 (till August): Information on Company, Year of Funding, Type, Amount Invested and Investors
Table 15.2 List of Funding Instances, 2014-2021 (till August): Information on Device and Indication
Table 16.1 List of Contract Manufacturing Organizations
Table 16.2 List of Medical Device Product Design and Development Companies
Table 17.1 General Guidelines for Market Authorization and Reimbursement for Medical Devices
Table 17.2 Device Classification: US
Table 17.3 Device Classification: Canada
Table 17.4 Data Requirements and Characteristics of Province-wide HTA Processes in Canada
Table 17.5 Device Classification: Mexico
Table 17.6 Device Classification: Europe
Table 17.7 List of CE Directives in Europe
Table 17.8 Conformity Assessment Modules in Europe
Table 17.9 Device Classification: Australia
Table 17.10 Medical Devices Reimbursement and Pricing Approval Process: Australia
Table 17.11 Device Classification: Brazil
Table 17.12 Device Classification: China
Table 17.13 Device Classification: India
Table 17.14 Device Classification: Japan
Table 17.15 Medical Devices Reimbursement Categories
Table 17.16 Device Classification: Medsafe
Table 17.17 Device Classification: Singapore
Table 17.18 Device Classification: South Korea
Table 17.19 Device Classification: South Africa
Table 17.20 Device Classification: Thailand
Table 17.21 Medical Devices Regulatory Landscape Summary
Table 17.22 Medical Devices Reimbursement Landscape Summary
Table 18.1 Large Volume Drug Device Combinations: List of Approved / Under Development Products
Table 18.2 Large Volume Wearable Injectors for Insulin Delivery: Annual Treatment Cost Information
Table 20.1 Company Snapshot: Medipacs
Table 20.2 Company Snapshot: Enable Injections
Table 20.3 Company Snapshot: Subcuject
Table 20.4 Company Snapshot: scPharmaceuticals
Table 20.5 Company Snapshot: Elcam Medical
Table 20.6 Company Snapshot: West Pharmaceutical Services
Table 20.7 Company Snapshot: Ypsomed
Table 20.8 Company Snapshot: Debiotech
Table 20.9 Company Snapshot: Sorrel Medical
Table 22.1 Large Volume Wearable Injectors: Overall Market Landscape
Table 22.2 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Status of Development
Table 22.3 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Device
Table 22.4 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Route of Administration
Table 22.5 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Therapeutic area
Table 22.6 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Technology
Table 22.7 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Dose
Table 22.8 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Mode of Injection
Table 22.9 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Volume / Storage Capacity (in mL)
Table 22.10 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Actuation Mechanism
Table 22.11 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Usability
Table 22.12 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Availability of Prefilled Drug Reservoir
Table 22.13 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Connectivity
Table 22.14 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Drug Compatibility
Table 22.15 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Drug Container
Table 22.16 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution of Developers by Year of Establishment
Table 22.17 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution of Developers by Company Size
Table 22.18 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution of Developers by Region of Headquarters
Table 22.19 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution of Developers by Location of Headquarters
Table 22.20 Leading Players: Distribution by Number of Products Manufactured
Table 22.21 Large Volume Drug Device Combinations: Distribution by Status of Development
Table 22.22 Large Volume Drug Device Combinations: Distribution by Type of Device
Table 22.23 Large Volume Drug Device Combinations: Distribution by Route of Administration
Table 22.24 Large Volume Drug Device Combinations: Distribution by Therapeutic Area
Table 22.25 Large Volume Drug Device Combinations: Distribution by Drug Compatibility
Table 22.26 Large Volume Drug Device Combinations: Distribution by Drug Container
Table 22.27 Large Volume Drug Device Combinations: Distribution by Type of Dose
Table 22.28 Large Volume Drug Device Combinations: Distribution by Mode of Injection
Table 22.29 Large Volume Drug Device Combinations: Distribution by Mechanism of Action
Table 22.30 Large Volume Drug Device Combinations: Distribution by Type of Technology
Table 22.31 Large Volume Drug Device Combinations: Distribution by Volume / Storage Capacity (in mL)
Table 22.32 Large Volume Drug Device Combinations: Distribution by Usability
Table 22.33 Large Volume Drug Device Combinations: Distribution of Developers by Year of Establishment
Table 22.34 Large Volume Drug Device Combination: Distribution of Developers by Company Size
Table 22.35 Large Volume Drug Device Combinations: Distribution of Developers by Location of Headquarters
Table 22.36 Leading Players: Analysis by Number of Drug Device Combination Products Manufactured
Table 22.37 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Status of Development
Table 22.38 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Type of Device
Table 22.39 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Volume / Storage Capacity (in mL)
Table 22.40 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Usability
Table 22.41 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Prefilled Drug Reservoir
Table 22.42 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Type of Dose
Table 22.43 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Combination Insulin
Table 22.44 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Availability of Non-Interoperable Device
Table 22.45 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Availability of Continuous Glucose Monitoring (CGM) / Blood Glucose Meters (BGM) System
Table 22.46 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Automated Insulin Delivery (AID) Feature
Table 22.47 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Availability of Automatic Insulin Delivery (AID) / Artificial Pancreas
Table 22.48 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Availability of Connectivity
Table 22.49 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Device Control Features
Table 22.50 Large Volume Wearable Injectors for Insulin Drugs: Distribution of Developers by Year of Establishment
Table 22.51 Large Volume Wearable Injectors for Insulin Drugs: Distribution of Developers by Company Size
Table 22.52 Large Volume Wearable Injectors for Insulin Drugs: Distribution of Developers by Location of Headquarters
Table 22.53 Leading Players: Analysis by Number of Insulin Drugs Products Manufactured
Table 22.54 Becton Dickinson: Annual Revenues, 2016- H1 2021 (USD Billion)
Table 22.55 Bespak: Annual Revenues, 2015- 2019 (GBP Million)
Table 22.56 Insulet: Annual Revenues, 2016-H1 2021 (USD Million)
Table 22.57 Roche: Annual Revenues, 2016-Q1 2021 (CHF Billion)
Table 22.58 West Pharmaceutical Services: Annual Revenues, 2016- H1 2021 (USD Billion)
Table 22.59 Eli Lilly: Annual Revenues, 2016- H1 2021 (USD Billion)
Table 22.60 Medtronic: Annual Revenues, 2016-Q1 2021 (USD Billion)
Table 22.61 Tandem Diabetes Care: Annual Revenues, 2016- H1 2021 (USD Million)
Table 22.62 Partnerships and Collaborations: Distribution by Year of Partnership
Table 22.63 Partnerships and Collaborations: Distribution by Type of Partner
Table 22.64 Partnerships and Collaborations: Distribution by Type of Partnership
Table 22.65 Partnerships and Collaborations: Distribution by Type of Device
Table 22.66 Partnerships and Collaborations: Distribution by Type of Technology
Table 22.67 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Table 22.68 Most Active Players: Distribution by Number of Partnership
Table 22.69 Most Active Players Distribution by Type of Partnership
Table 22.70 Partnerships and Collaborations: Regional Distribution
Table 22.71 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 22.72 Patent Analysis: Distribution by Type of Patent
Table 22.73 Patent Analysis: Distribution by Publication Year
Table 22.74 Patent Analysis: Distribution by Issuing Authority / Patent Offices Involved
Table 22.75 Patent Analysis: Distribution by CPC Symbols
Table 22.76 Patent Analysis: Cumulative Distribution by Type of Organization
Table 22.77 Leading Industry Players: Distribution by Number of Patents
Table 22.78 Leading Non-Industry Players: Distribution by Number of Patents
Table 22.79 Patent Analysis: Leading Individual Assignees
Table 22.80 Leading Industry Players: Benchmarking by Patent Characteristics (CPC Symbols)
Table 22.81 Patent Analysis: Distribution of Patents by Age, 2001-2021
Table 22.82 Large Volume Wearable Injectors: Patent Valuation
Table 22.83 Clinical Trial Analysis: Scope and Methodology
Table 22.84 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year
Table 22.85 Clinical Trial Analysis: Distribution by Study Design
Table 22.86 Clinical Trial Analysis: Distribution by Number of Registered Trials
Table 22.87 Clinical Trial Analysis: Distribution by Therapeutic area
Table 22.88 Clinical Trial Analysis: Geographical Distribution by Number of Clinical Trials
Table 22.89 Clinical Trial Analysis: Geographical Distribution by Number of Patients Enrolled
Table 22.90 Clinical Trial Analysis: Distribution by Clinical Endpoints
Table 22.91 Funding and Investments: Distribution by Year of Investment
Table 22.92 Funding and Investments: Distribution by Year and Amount Invested
Table 22.93 Funding and Investments: Distribution by Type of Funding
Table 22.94 Funding and Investments: Distribution by Year and Type of Funding
Table 22.95 Funding and Investments: Distribution by Type of Funding and Amount Invested
Table 22.96 Funding and Investments: Distribution by Type of Device and Amount Invested
Table 22.97 Funding and Investments: Distribution by Target Disease Indication
Table 22.98 Most Active Players: Distribution by Number of Funding Instances
Table 22.99 Most Active Players: Distribution by Amount Invested
Table 22.100 Key Investors: Analysis by Number of Instances
Table 22.101 Funding and Investment: Distribution by Geography
Table 22.102 Healthcare Insurance Coverage in the US: Distribution by Type of Coverage
Table 22.103 Healthcare Insurance Coverage in Canada: Distribution by Type of Coverage
Table 22.104 Healthcare Insurance Coverage in the UK: Distribution by Type of Coverage
Table 22.105 Healthcare Insurance Coverage in France: Distribution by Type of Coverage
Table 22.106 Healthcare Insurance Coverage in Germany: Distribution by Type of Coverage
Table 22.107 Healthcare Insurance Coverage in Italy: Distribution by Type of Coverage
Table 22.108 Healthcare Insurance Coverage in Spain: Distribution by Type of Coverage
Table 22.109 Healthcare Insurance Coverage in Australia: Percentage Distribution by Type of Coverage
Table 22.110 Medical Devices Review / Approval Process: Brazil
Table 22.111 Healthcare Insurance Coverage in China: Percentage Distribution by Type of Coverage
Table 22.112 Healthcare Insurance Coverage in Israel: Percentage Distribution by Type of Coverage
Table 22.113 Healthcare Insurance Coverage in Japan: Percentage Distribution by Type of Coverage
Table 22.114 Healthcare Insurance Coverage in New Zealand: Percentage Distribution by Type of Coverage
Table 22.115 Healthcare Insurance Coverage in South Korea: Percentage Distribution by Type of Coverage
Table 22.116 Healthcare Insurance Coverage in Taiwan: Percentage Distribution by Type of Coverage
Table 22.117 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, Conservative, Base and Optimistic Scenarios, 2021-2035 (By Value)
Table 22.118 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device, Conservative, Base and Optimistic Scenarios, 2021-2035 (By Value)
Table 22.119 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability, Conservative, Base and Optimistic Scenarios, 2021-2035 (By Value)
Table 22.120 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenarios, 2021-2035 (By Value)
Table 22.121 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, Conservative, Base and Optimistic Scenarios, 2021-2035 (By Value)
Table 22.122 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Type of Device, Conservative, Base and Optimistic Scenarios, 2021-2035 (By Value)
Table 22.123 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Usability, Conservative, Base and Optimistic Scenarios, 2021-2035 (By Value)
Table 22.124 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenarios, 2021-2035 (By Value)
Table 22.125 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, Conservative, Base and Optimistic Scenarios, 2021-2035 (By Value)
Table 22.126 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Type of Device, Conservative, Base and Optimistic Scenarios, 2021-2035 (By Value)
Table 22.127 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Usability, Conservative, Base and Optimistic Scenarios, 2021-2035 (By Value)
Table 22.128 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenarios, 2021-2035 (By Value)
Table 22.129 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific, Conservative, Base and Optimistic Scenarios, 2021-2035 (By Value)
Table 22.130 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Type of Device, Conservative, Base and Optimistic Scenarios, 2021-2035 (By Value)
Table 22.131 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Usability, Conservative, Base and Optimistic Scenarios, 2021-2035 (By Value)
Table 22.132 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenarios, 2021-2035 (By Value)
Table 22.133 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America, Conservative, Base and Optimistic Scenarios, 2021-2035 (By Value)
Table 22.134 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America: Distribution by Type of Device, Conservative, Base and Optimistic Scenarios, 2021-2035 (By Value)
Table 22.135 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America: Distribution by Usability, Conservative, Base and Optimistic Scenarios, 2021-2035 (By Value)
Table 22.136 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenarios, 2021-2035 (By Value)
Table 22.137 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Conservative, Base and Optimistic Scenarios, 2021-2035 (By Value)
Table 22.138 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Type of Device, Conservative, Base and Optimistic Scenarios, 2021-2035 (By Value)
Table 22.139 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Usability, Conservative, Base and Optimistic Scenarios, 2021-2035 (By Value)
Table 22.140 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenarios, 2021-2035 (By Value)
Table 22.141 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, Conservative, Base and Optimistic Scenarios, 2021-2035 (By Volume)
Table 22.142 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device, Conservative, Base and Optimistic Scenarios, 2021-2035 (By Volume)
Table 22.143 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability, Conservative, Base and Optimistic Scenarios, 2021-2035 (By Volume)
Table 22.144 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenarios, 2021-2035 (By Volume)
Table 22.145 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, Conservative, Base and Optimistic Scenarios, 2021-2035 (By Volume)
Table 22.146 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Type of Device, Conservative, Base and Optimistic Scenarios, 2021-2035 (By Volume)
Table 22.147 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Usability, Conservative, Base and Optimistic Scenarios, 2021-2035 (By Volume)
Table 22.148 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenarios, 2021-2035 (By Volume)
Table 22.149 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, Conservative, Base and Optimistic Scenarios, 2021-2035 (By Volume)
Table 22.150 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Type of Device, Conservative, Base and Optimistic Scenarios, 2021-2035 (By Volume)
Table 22.151 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Usability, Conservative, Base and Optimistic Scenarios, 2021-2035 (By Volume)
Table 22.152 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenarios, 2021-2035 (By Volume)
Table 22.153 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific, Conservative, Base and Optimistic Scenarios, 2021-2035 (By Volume)
Table 22.154 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Type of Device, Conservative, Base and Optimistic Scenarios, 2021-2035 (By Volume)
Table 22.155 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Usability, Conservative, Base and Optimistic Scenarios, 2021-2035 (By Volume)
Table 22.156 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenarios, 2021-2035 (By Volume)
Table 22.157 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America, Conservative, Base and Optimistic Scenarios, 2021-2035 (By Volume)
Table 22.158 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America: Distribution by Type of Device, Conservative, Base and Optimistic Scenarios, 2021-2035 (By Volume)
Table 22.159 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America: Distribution by Usability, Conservative, Base and Optimistic Scenarios, 2021-2035 (By Volume)
Table 22.160 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenarios, 2021-2035 (By Volume)
Table 22.161 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Conservative, Base and Optimistic Scenarios, 2021-2035 (By Volume)
Table 22.162 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Type of Device, Conservative, Base and Optimistic Scenarios, 2021-2035 (By Volume)
Table 22.163 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Usability, Conservative, Base and Optimistic Scenarios, 2021-2035 (By Volume)
Table 22.164 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenarios, 2021-2035 (By Volume)
Table 22.165 Global Large Volume Wearable Injectors Market for Insulin, Conservative, Base and Optimistic Scenarios, 2021-2035
Table 22.166 Global Large Volume Wearable Injectors Market for Insulin: Distribution by Type of Device, Conservative, Base and Optimistic Scenarios, 2021-2035
Table 22.167 Global Large Volume Wearable Injectors Market for Insulin: Distribution by Usability, Conservative, Base and Optimistic Scenarios, 2021-2035
Table 22.168 Large Volume Wearable Injectors Market for Insulin in North America, Conservative, Base and Optimistic Scenarios, 2021-2035
Table 22.169 Large Volume Wearable Injectors Market for Insulin in North America: Distribution by Type of Device, Conservative, Base and Optimistic Scenarios, 2021-2035
Table 22.170 Large Volume Wearable Injectors Market for Insulin in North America: Distribution by Usability, Conservative, Base and Optimistic Scenarios, 2021-2035
Table 22.171 Large Volume Wearable Injectors Market for Insulin in Europe, Conservative, Base and Optimistic Scenarios, 2021-2035
Table 22.172 Large Volume Wearable Injectors Market for Insulin in Europe: Distribution by Type of Device, Conservative, Base and Optimistic Scenarios, 2021-2035
Table 22.173 Large Volume Wearable Injectors Market for Insulin in Europe: Distribution by Usability, Conservative, Base and Optimistic Scenarios, 2021-2035
Table 22.174 Large Volume Wearable Injectors Market for Insulin in Asia Pacific, Conservative, Base and Optimistic Scenarios, 2021-2035
Table 22.175 Large Volume Wearable Injectors Market for Insulin in Asia Pacific: Distribution by Type of Device, Conservative, Base and Optimistic Scenarios, 2021-2035
Table 22.176 Large Volume Wearable Injectors Market for Insulin in Asia Pacific: Distribution by Usability, Conservative, Base and Optimistic Scenarios, 2021-2035
Table 22.177 Large Volume Wearable Injectors Market for Insulin in Latin America, Conservative, Base and Optimistic Scenarios, 2021-2035
Table 22.178 Large Volume Wearable Injectors Market for Insulin in Latin America: Distribution by Type of Device, Conservative, Base and Optimistic Scenarios, 2021-2035
Table 22.179 Large Volume Wearable Injectors Market for Insulin in Latin America: Distribution by Usability, Conservative, Base and Optimistic Scenarios, 2021-2035
Table 22.180 Large Volume Wearable Injectors Market for Insulin in Middle East and North Africa, Conservative, Base and Optimistic Scenarios, 2021-2035
Table 22.181 Large Volume Wearable Injectors Market for Insulin in Middle East and North Africa: Distribution by Type of Device, Conservative, Base and Optimistic Scenarios, 2021-2035
Table 22.182 Large Volume Wearable Injectors Market for Insulin in Middle East and North Africa: Distribution by Usability, Conservative, Base and Optimistic Scenarios, 2021-2035
The following companies and organizations have been mentioned in the report.
Discounts available for multiple report purchases
sales@rootsanalysis.com